{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:52:20Z","timestamp":1792079540919,"version":"4.4.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.1182\/blood.2026035095","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:31:51Z","timestamp":1792078311000},"page":"1948-1950","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["The enigma of rapid response vs safety in AL amyloidosis"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2026101511314961500_bib1","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2025032897","article-title":"A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis","volume":"148","author":"Kastritis","year":"2026","journal-title":"Blood"},{"issue":"1","key":"2026101511314961500_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2026101511314961500_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-021-00510-7","article-title":"Impact of early response on outcomes in AL amyloidosis following treatment with frontline bortezomib","volume":"11","author":"Ravichandran","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026101511314961500_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","article-title":"The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018","volume":"13","author":"Palladini","year":"2023","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026101511314961500_bib5","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41375-021-01297-z","article-title":"Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design","volume":"35","author":"Vaxman","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026101511314961500_bib6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood-2025-691","article-title":"Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd) [abstract]","volume":"146","author":"Sanchorawala","year":"2025","journal-title":"Blood"},{"issue":"7","key":"2026101511314961500_bib7","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3324\/haematol.2024.285145","article-title":"Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study","volume":"109","author":"Shen","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"2026101511314961500_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ajh.27179","article-title":"Reduced early mortality with daratumumab-based frontline therapy in AL amyloidosis: a retrospective cohort study","volume":"99","author":"Chakraborty","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"2026101511314961500_bib9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3324\/haematol.2023.283325","article-title":"Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival","volume":"109","author":"Oubari","year":"2024","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/16\/1948\/2594921\/blood_bld-2026-035095-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/16\/1948\/2594921\/blood_bld-2026-035095-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:31:52Z","timestamp":1792078312000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/16\/1948\/571435\/The-enigma-of-rapid-response-vs-safety-in-AL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":9,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026035095","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,10,15]]}}}